Background: Chronic ulcerations affect millions of people in the world and is a huge challenge to the health systems to manage. Wounds are a multibillion dollar problem world-wide 28 billion / year in primary wound diagnosis and 31.7 billion / year in secondary diagnosis in the United States.4,5 Managing these complex wounds can be expensive and costly being able to evaluate products and provide real world evidence is critical in helping clinicians to understand and use these products appropriately. Oxygen helps stimulate vascular endothelial growth factor (VEGF) and other signalling pathways that promote this process, improving blood supply to the area and speeding up healing. Granulox® is a medical device spray that contains highly purified porcine haemoglobin. When applied to a wound, it binds to oxygen from the surrounding air and transports it directly to the wound bed. This localized oxygen delivery supports the healing process, especially in chronic or non-healing wounds . Aim: Determine the impact of Granulox® on wounds in acute vascular setting. Methodology: We examined 8 vascular patients with a range of wound types. The Granulox® spray was initiated early in some cases and on older wounds we used digital photography to monitor progress. We used SnapshotNIR-kent infrared photography to demonstrate increased oxygenation over time in the wound bed. Results: Improved healing rates were observed and early start to treatment along with good wound bed preparation saw healing rates in wounds that were determined to be unhealable. Conclusion Granulox® improves healing and pain in wounds which fail to improve with standard treatment. Granulox in this case series reduced pain scores and increased oxygen the wound bed over time after four weeks of use. The advantages are that it is Non-invasive and easy to apply. It also demonstrated more research needed around measuring oxygen in the wound bed.